Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liquid biopsy
Biotech
Eisai's abandoned Enhertu challenger set to live on at BlissBio
Eisai once identified BB-1701 as a potential best-in-class molecule, citing its eribulin-based payload-linker technology as a differentiator.
Nick Paul Taylor
Mar 21, 2025 7:20am
JPM25: Guardant posts 31% sales gain as cancer blood tests grow
Jan 13, 2025 9:19am
Guardant awarded $292M in false advertising suit against Natera
Nov 26, 2024 10:45am
EU court hands Illumina consolation prize over Grail deal
Sep 3, 2024 12:21pm
Flying solo, Grail to cut 30% of staff, narrow cancer test focus
Aug 14, 2024 11:30am
FDA approves Guardant’s colorectal cancer screening blood test
Jul 29, 2024 11:00am
